Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Trial to Evaluate the Efficacy of a Dyslipidemic Therapy in Mexican Population

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03696940
Recruitment Status : Active, not recruiting
First Posted : October 5, 2018
Last Update Posted : February 26, 2019
Sponsor:
Collaborator:
Instituto Nacional de Salud Publica, Mexico
Information provided by (Responsible Party):
Laboratorios Grossman, S.A.

Brief Summary:

Clinical Trial Phase III, experimental, simple blind, randomized with two treatment groups, multicentric, longitudinal, to evaluate the therapuetic efficacy to dislipydemias in mexican adult population. This trial includes homogeneus populations that could be comparable by their disease condition, biologic characteristics and sociodemographics characteristics.

2 Treatment groups: Experimental Group: Oral Administration of L-carnitine (1g) + Oral Atorvastatin (20mg), every 24 hours for 6 months.

Active control group: Oral Administration of Atorvastatin 20mg every 24 hours for 6 months.

Sample Size: 120 subjects, females or males between 35 to 75 years old. Laboratory tests: Hematic biometry, quimical blood components, electrocardiogram and pregnancy urinary test.


Condition or disease Intervention/treatment Phase
Dyslipidemias Cardiovascular Risk Factor Drug: L-Carnitine 500Mg Oral Tablet + Atorvastatin 10 mg Drug: Atorvastatin 10mg Phase 3

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Longitudinal
Masking: Single (Participant)
Masking Description: Simple Blinded
Primary Purpose: Treatment
Official Title: Estudio clínico Fase III Para Evaluar la Eficacia terapéutica en Pacientes Mexicanos Con Dislipidemia Mediante el Uso vía Oral de L-Carnitina + Atorvastatina Comparado Con Atorvastatina
Actual Study Start Date : May 28, 2018
Estimated Primary Completion Date : March 1, 2019
Estimated Study Completion Date : August 31, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Experimental Group
2 tablets of: L-Carnitine 500Mg Oral Tablet + Atorvastatin 10 mg
Drug: L-Carnitine 500Mg Oral Tablet + Atorvastatin 10 mg
Oral administration of 2 tablets of atorvastatin 10 mg (each one) every 24 hours for 6 months.
Other Name: Experimental Group

Active Comparator: Control Group
2 tablets of: Atorvastatin 10 mg
Drug: Atorvastatin 10mg
Oral administration of 2 tablets atorvastatin 10 mg (each one) every 24 hours for 6 months.
Other Name: Active control group




Primary Outcome Measures :
  1. Efficacy of experimental treatment by the change in Cholesterol LDL [ Time Frame: 6 months ]
    Evaluate the change of atorvastatin + l-carnitine vs. atorvastatin alone for dyslipidemia, through change of C-LDL in mg/dl


Secondary Outcome Measures :
  1. Efficacy of experimental treatment by the change in Cholesterol no-HDL [ Time Frame: 6 months ]
    Evaluate the change of Cholesterol no-HDL in Mexican adults with dyslipidemia through the use of oral route L-carnitine + atorvastatin in comparison with the use of Atorvastatin, after six months of treatment.

  2. Efficacy of experimental treatment by the change in Total serum Cholesterol [ Time Frame: 6 months ]
    Evaluate the change of serum levels of Cholesterol in mg/dl in Mexican adults with dyslipidemia through the use of oral route L-carnitine + atorvastatin in comparison with the use of Atorvastatin, after six months of treatment.

  3. Efficacy of experimental treatment by the change in Triglycerides [ Time Frame: 6 months ]
    Evaluate the reduction of serum levels of Triglycerides in mg/dl in Mexican adults with dyslipidemia through the use of oral route L-carnitine + atorvastatin in comparison with the use of Atorvastatin, after six months of treatment

  4. Efficacy of experimental treatment by the change in Cholesterol HDL [ Time Frame: 6 months ]
    Evaluate the change of serum levels of Cholesterol HDL in mg/dl in Mexican adults with dyslipidemia through the use of oral route L-carnitine + atorvastatin in comparison with the use of Atorvastatin, after six months of treatment

  5. Incidence of Treatment-Emergent Adverse Events (safety and tolerability) [ Time Frame: 6 months ]
    Evaluate the incidence, of serious and non-serious adverse events related through the oral route administration of L-carnitine + atorvastatin in comparison with the use of Atorvastatin, after six months of treatment in the subjects participating in the study



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   35 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Mexicans between 35 and 75 years of age.
  • Gender indistinct.
  • Patient with abnormal lipid profile considered as serum levels of Cholesterol LDL of 100mg/dl or greater, obtained by laboratory parameters.
  • Not being under pharmacologic treatment to manage its dyslipidemia or accept to suspend current treatment and be evaluated for inclusion in the next 3 weeks starting on the day of initial evaluation.
  • Women in fertile stage with a safe, hormonal-free family planning method. A safe planning method includes surgical methods in women, intrauterine device that doesn't release progestines and use of preservative in all their sexual relations.
  • Women in fertile stage who don't wish to become pregnant during their participation in the study.
  • Post-menopause women or with hysterectomy history.
  • Have a fixed and/or mobile telephone and accept to receive calls from the site for study processes.
  • Grant their duly informed consent.

Exclusion Criteria:

  • Subject lacking the mental capacity to understand the processes which imply their participation in the study and thus, not capable of granting their participation in a voluntary manner
  • History of hypersensitivity to the medicines being studied.
  • Daily intake of at least 240 mL of grape juice or sporadic ingestion of 1 liter.
  • Potentially fertile women without a safe family planning method, who wish to become pregnant during the study, are already pregnant or in lactation period.
  • Having on Globorisk scale for Mexicans, or as an associated risk factor, a high stratification for cardiovascular risk.
  • Basal laboratory values with elevation of ALT 1.5 times larger than the upper limit considered normal according to international units.

Basal laboratory values with elevation of CPK not attributable to physical activity.

  • Subjects who are under anticoagulant treatment, suffer from coagulation disorders, or any circumstance which contraindicates the taking of a blood.
  • History of acute myocardial infarction, unstable angina, some confirmed coronopathy, arrhythmias, congestive cardiac failure or cerebrovascular disease.
  • History of muscular conditions of the genetic type or of rhabdomyolysis in the patient or first degree relative.
  • History or diagnose of congenital hepatic disorders, chronic infection by hepatitis virus, hepatitis with fatty liver, alcoholic hepatitis, primary biliary cirrhosis, primary sclerosis, cholangitis or hepatic failure.
  • History or diagnose of congenital renal disorders, chronic renal failure, acute renal damage or nephritic syndrome.
  • History of infection by Human Immunodeficiency Virus.
  • History of Acute or Chronic Pancreatitis.
  • History of the following endocrine diseases: non controlled Diabetes Mellitus, lipodystrophy, thyroid disorders, Cushing Syndrome and or Polycystic Ovary Syndrome.
  • Diseases which compromise immunity such as Systemic Lupus Erythematous, Rheumatoid Arthritis, Antiphospholipid Antibodies Syndrome or Psoriasis.

Diseases by deposit such as Gaucher Disease, disease by glycogen deposit, Tay Sachs juvenile disease or Niemann Pick Disease.

  • Diagnose of Kawasaki Disease, Werner Syndrome, intermittent acute Porphyria, Idiopathic Hyperkalemia or Klinefelter Syndrome
  • Suffer from Idiopathic Hyperkalemia, Klinefelter Syndrome, Werner Syndrome, Kawasaki Disease or Porphyria.
  • History of epilepsy.
  • History or diagnose of alcoholism.
  • Intake of more than 20 grams of alcohol per day.
  • User of marihuana.
  • User of illegal drugs.
  • Intake of medicines with pharmacologic interaction which increase or decrease the efficacy of L Carnitine and or atorvastatin or alter the lipids in blood such as Erythromycin, Telithromycin and Clarithromycin. Azole antifungi as Ketoconazole, Itraconazole, Fluconazole and Nefazodone. Quercetin, Amiodarone, Aprepitant, Cimetidine, Ciprofloxacin, Cyclosporine, Diltiazem, Imatinib, Echinacea, Enoxacin, Ergotamine, Metronidazole, Mifepristone, Tofisopam, Gestodene, Verapamil, Mibefradil, Fluoxetine, Phenobarbital, Carbamazepine, Phenytoin, Rifampin, Modafinil, Glucocorticoids, Felbamate, Rosiglitazone, Griseofulvin, Pioglitazone, Gemfibrozil, Clofibrate, Fenofibrate, Niacin, Nefazodone, Cholestyramine, Colchicine, Colestipol, Primidone, Topiramate, Troglitazone, Rifabutin, Digoxin, Thiazides, anabolic Steroids, Progestogens, Estrogens, Danazol, Amiodarone, fibric Acid, docosahexaenoic acid, Isotretinoine, Immunosuppressives, protease inhibitors of HIV or of the Hepatitis C Virus, Inhibitors of the cotransport of sodium glucose, Tamoxifen, Raloxifene, non selective Beta blockers, biliary acid sequestrants, asparginase, Sirolimus and Interferon.
  • Patients who have been diagnosed with terminal conditions.
  • Patients with recent Cancer diagnose or undergoing any type of therapy for same.
  • Patients who have suffered skin cancer not of the melanoma type and have been cured and haven't been on treatment for at least 1 year before the start of their participation in the study may enter.
  • Patients under lipid lowering treatment and who, because of their clinical condition aren't candidates to the period of lavage or detoxification; or well reject it.
  • Being participating in another clinical trial or having concluded their participation in the 30 days previous to beginning their participation in this study.
  • Any other which, at the Investigator's criteria, puts at risk the safety of the participant and or interferes with the results of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03696940


Locations
Layout table for location information
Mexico
Laboratorios Grossman Sa
Mexico City, Mexico, 04040
Sponsors and Collaborators
Laboratorios Grossman, S.A.
Instituto Nacional de Salud Publica, Mexico
Investigators
Layout table for investigator information
Principal Investigator: Aurelio Cruz Valdez, PhD Instituto Nacional de Salud Pública
Principal Investigator: José Flores Figueroa, PhD JM Research, SC
  Study Documents (Full-Text)

Documents provided by Laboratorios Grossman, S.A.:
Study Protocol  [PDF] August 3, 2017


Additional Information:
Publications of Results:
Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corrà U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FDR, Løchen ML, Löllgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WMM, Binno S; ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016 Aug 1;37(29):2315-2381. doi: 10.1093/eurheartj/ehw106. Epub 2016 May 23.

Layout table for additonal information
Responsible Party: Laboratorios Grossman, S.A.
ClinicalTrials.gov Identifier: NCT03696940    
Other Study ID Numbers: GMX-001-2017
First Posted: October 5, 2018    Key Record Dates
Last Update Posted: February 26, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Atorvastatin
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors